Ose Immunotherapeutics shares fall on AbbVie partnership delay
NegativeFinancial Markets
Ose Immunotherapeutics has seen a decline in its shares following a delay in its partnership with AbbVie. This news is significant as it raises concerns about the future of their collaborative projects and could impact investor confidence. Delays in partnerships can often lead to uncertainty in the biotech sector, affecting not only the companies involved but also their stakeholders.
— Curated by the World Pulse Now AI Editorial System